The U.S. Food and Drug Administration on Friday released a letter to Allergan Inc. saying that the company’s marketing and advertising efforts for Aczone, an acne treatment, are misleading.
The letter, addressed to Allergan Chief Executive David E.I. Pyott, states Aczone’s effectiveness is overstated and that risk factors associated with the drug are omitted from a print advertisement.
Read full story via bizjournals:.
Discussion
No comments for “FDA: Allergan Aczone ads were misleading – Los Angeles Business from bizjournals:”